

SHIC FAST TRACK

2026, Oct. 8 (Thu.)

Pitch 10-11 AM / Awards 4-4:30 PM

 **PACIFICO Yokohama**
BioJapan at BioJapan 2026

JBA
Japan Bioindustry Association

iPark

JBA
Japan Bioindustry Association

iPark

SHIC Fast Track 2026 Application Guidelines

iPark Institute, Co. Ltd. (iPi)
July, 2026


SHIC FAST TRACK @ BioJapan 2026

Event Name	SHIC FAST TRACK
Host / In Cooperation With	iPark Institute, Co. Ltd. (iPi) / Japan Bioindustry Association (JBA)
Date	Thursday, October 8, 2026 (Day 2 of BioJapan 2026)
Time & Venue	Pitch session: 10:00–11:00, Annex Hall "Investment Forum" Results & Awards: 16:00–16:30, Main Stage (Exhibition Hall)
Format	On-site only (no streaming or archive)
No. of Companies	Up to 4 companies
Pitch Format	6-min presentation + 6-min Q&A = 12 min/company (in English)
Eligible Applicants	Startups and academia-derived seeds in the drug-discovery / biotech field (Asia-based, with global ambitions)

[Related Program] In addition to SHIC FAST TRACK, iPi also runs "Innovation Tiger," a domestic pitch program held in Shonan. The two programs are operated independently.

Two Selection Routes to SHIC in Boston 2026

Beyond the "Innovation Tiger" main-selection route, the newly established "SHIC FAST TRACK (BioJapan, October)" opens a second route to reach the SHIC (Boston 2026) stage.



Innovation Tiger finalists will be granted participation rights!

A matching event themed on connecting Asia and the U.S., delivering “black-boxed” Asian seeds:
Shonan Health Innovation Conference (SHIC) in Boston

SHIC in Boston 2024

of Participating
Startups: 16

Countries:
Japan • Korea



SHONAN HEALTH INNOVATION CONFERENCE
in Boston

December 4th (Wed), 2024
Le Méridien Boston Cambridge
20 Sidney St, Cambridge, MA 02139 United States

Morning	1 on 1 partnering with selected Asian bio-ventures and U.S. VCs Keynote speech, Fireside Chat, and Startup pitch session
Afternoon	Andy Plump, M.D., Ph.D. [President, Research & Development, Takeda Pharmaceutical Company Limited] Michael E. Mendelsohn, M.D. [Founder, Board Chairman, and Chief Strategic Officer, Caridian Pharmaceuticals] Daniel Kemp, Ph.D. [Chief Executive Officer, Shionoi Therapeutics Inc.]
Dinner	Cocktail Party

Sponsored by **KJRM** **Mitsubishi Corporation** **SMBC** **incubate@shonan**

Cooperation by Japan External Trade Organization New York (JETRO New York)
Consulate-General of Japan in Boston
Takeda Pharmaceutical Company Limited.

Hosted by **iPark Institute Co., Ltd.**

16 VCs/CVCs/Pharma

ARCH Ventures, Flagship Pioneering, RA Capital Management, EQT Partners, Curie Bio, All Terrain Partners, Fast Track Initiative, Mass Medical Angels, MP Healthcare, Fortunate Capital, Eli Lilly, Merck, Astellas, Takeda, Chugai, others



SHIC in Boston 2025

of Participating
Startups: 18

Countries :
Japan • Korea • Taiwan



SHONAN HEALTH INNOVATION CONFERENCE
in Boston

November 19th (Wed), 2025
Lab Central 700 Main St, Cambridge, MA 02139
LabCentral Tour Academic & Mentoring Sessions Reception

November 20th (Thu), 2025
Le Méridien Boston Cambridge 20 Sidney St, Cambridge, MA 02139

1-on-1 Partnering Session	9:00 AM – 11:30 AM / 1:30 PM – 5:00 PM A luncheon session is scheduled at 12:00 PM.
Panel Discussion	4:00 PM – 5:00 PM A networking reception will follow the panel discussion.

Sponsored by **KJRM** **Mitsubishi Corporation** In partnership with **Lab Central**

Cooperation by **Consulate-General of Japan in Boston** Hosted by **iPark Institute Co., Ltd.**

21 VCs/CVCs/Pharma

Curie.Bio, RA Capital Management, MPM BioImpact, , Fast Track Initiative, AN Venture Partners, Pfizer, AbbVie, Gemseki Investment, Astellas Venture Management, /Blue Goose Capital, Ingenious Global Venture Partners, Northpond Ventures, HelixPoint Capital, FUJIFILM Holdings America Corporation, Kastor Capital, HEVOLUTION, Kissei America, Meiji Pharma USA, Chiesi, Eisai, Chugai Venture Fund



SHIC in Boston 2026 coming soon!



Judges — Areas of Interest



MSD K.K.
Koji Yashiro

Director, Pacific Business Development & Licensing



Astellas Pharma Inc.
Hide Goto

Head of Open Innovation Management



ReachMed Partners LLC
Masanori Sato

President

Therapeutic Areas

Oncology, Vaccines, Infectious diseases,
Cardio,metabolic disorders Immunology, Neuroscience,
Ophthalmology

Ophthalmology, Otology, Rare diseases, etc.

All areas

Modalities

Any modalities

Cells, Genes, Nucleic Acids, etc.

Any modalities

Stage

All Stages

Basic Research ~ Preclinical Research

All stages




Application Guidelines for Presenting Companies

Eligible Applicants	Startups in the drug-discovery / biotech field (companies with global ambitions), and researchers / academia-derived seeds aiming for commercialization
Stage	Seed to Later Stage
Field	Drug discovery and life sciences in general
Benefits	- Presenters pitch at a pre-selection session during BioJapan (one of Asia's largest partnering events) — gaining exposure to pharmaceutical companies and investors (Post-event) exposure via photos and article reports - The top company receives the right to join "SHIC in Boston 2026" (a closed partnering conference hosted by iPark with U.S. investors and pharmaceutical companies)
Schedule	- Applications: Jul 24 – Aug 31, 2026 - Document screening & notification: Sep 25, 2026 - Pitch: Thu, Oct 8, 2026 @ BioJapan (PACIFICO Yokohama) - Results & awards: same day - SHIC in Boston: Dec 9–10, 2026 (tentative)
No. of Presenters	Up to 4 companies
Selection Method	- Document screening (conducted independently by iPark) - Selection based on the application form entries and submitted materials
How to Apply	- After confirming your eligibility, please complete and submit the form below. https://forms.gle/DqExzQYzVxVgdfKR6
Other Notes	- The pitch and Q&A will be conducted in English - Presenters appear on-site at the BioJapan venue (PACIFICO Yokohama) (offline event) - Participation is free of charge
Contact	shic@shonan-ipark.com

Eligibility & Timeline

Eligibility

- Startups in the drug-discovery / biotech field (early to late stage, with global ambitions)
- Researchers / academia-derived seeds aiming for commercialization





Frequently Asked Questions (FAQ)

Q. Do I need to create a video for the application?

A. No. You apply simply by filling in the form. Some questions can be answered using your existing non-confidential materials, and no time-consuming preparation such as a pitch video is required.

Q. Do the application materials have to be in English?

A. The pitch itself must be in English, but application materials may be submitted in Japanese.

Q. How is this different from other pitch events?

A. It is one of the few pitch competitions in Asia dedicated to life sciences such as pharma and drug discovery. Finalists are given priority access to partnering opportunities with overseas investors in Boston (SHIC 2026).

Q. Are there any participation fees or costs?

A. Participation is free of charge.

Q. Will travel costs to Boston be covered?

A. Partially subsidized last year; TBD (under review) for this year.

Q. Can I apply without a Japanese entity (i.e., based overseas)?

A. Yes. Startups and academia across Asian countries are eligible, regardless of whether you have a Japanese entity.

Q. Are there any disadvantages if I am not selected in the screening?

A. No. The screening is conducted independently by iPark. Only the selected finalists are made public; your application and its result are not disclosed to anyone other than JBA and iPark. There is no significant downside to not being selected, so please feel free to apply.

Q. What is the difference between Innovation Tiger and SHIC FAST TRACK?

A. Both are pitch selections ultimately aiming for a presentation slot at "SHIC in Boston 2026," but the routes differ.

Innovation Tiger: Selects SHIC presenters through regional preliminaries across Asia and a final round, with mentoring by experts such as pharma BD professionals and investors (plus prize money).

SHIC FAST TRACK: Selects SHIC presenters directly via a pitch at the BioJapan venue in October, without a separate final round.

The two routes run independently and converge at "SHIC in Boston 2026."

Q. I have already applied to Innovation Tiger. May I also apply to SHIC FAST TRACK?

A. Yes. As the two programs are independent selection routes, you may apply to either or both.

Appendix

2025 Highlights & Track Record



Tigers (Judges)

Takeda Pharmaceutical Company Limited

Eli Lilly and Company K.K.

CSL Behring K.K.

Eisai Co., Ltd.

MSD K.K.

DAIICHI SANKYO

Astellas Pharma Inc.

AN Venture Partners

Startup Finalists

	Lmito Therapeutics
	BFACT
	Galux
	Glaceum
	SmartinBIO
	InnoCure Therapeutics
	PURMX Therapeutics
	MediMabBio
	Senno Therapeutics
	Liid Pharmaceuticals
	SML Biopharm
	HiLung
	DiveRadGel
	Pilatus Biosciences
	FerroptoCure
	Trust Bio-sonics

Key Differentiators

- ◆ Large-scale sourcing across Japan, Korea & Taiwan
- ◆ Direct access to Tigers (judges) and mentors
- ◆ Science-driven BD mentoring by industry experts
- ◆ Access to meetings with global VCs and pharma in Boston (SHIC)